ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

Core Insights - ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD) [1][3] - The company will participate in two healthcare conferences in September 2025, showcasing its commitment to engaging with investors and the healthcare community [1][2] Conference Participation - ProKidney will attend the Citi Biopharma Back to School Conference in Boston on September 3, 2025, at 10:30 am ET, in a fireside chat format [1] - The company will also participate in the Morgan Stanley Global Healthcare Conference in New York on September 8, 2025, at 7:00 am ET, also in a fireside chat format [2] Product Development - ProKidney's lead product candidate, rilparencel (REACT), is a first-in-class, patented autologous cellular therapy aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes [3] - The product is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study, highlighting the company's focus on innovative treatments for CKD [3]